SCHEMBL24591663

SCHEMBL24591663

CCCCCCCCC(CCCCCCC)OCCN(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 5/20 0.48
PLA2G1B P04054 1/20 0.37
PLA2G2A P14555 1/20 0.37
LMNA P02545 3/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2B P18089 1/20 0.35
CHRM3 P20309 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
SLC6A4 P31645 1/20 0.35
ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25799517 1.00 DNM1 (0.48) DNM1PLA2G1BPLA2G2ALMNATSHR
SCHEMBL23674138 0.92 DNM1 (0.45) DNM1PLA2G1BPLA2G2ALMNATSHR
SCHEMBL26042156 0.90 DNM1 (0.52) DNM1PLA2G1BPLA2G2ATSHRKDM4E
SCHEMBL20018200 0.89 DNM1 (0.56) DNM1TSHRKDM4EALDH1A1
SCHEMBL29246564 0.89 DNM1 (0.56) DNM1TSHRKDM4EALDH1A1
SCHEMBL24562835 0.89 DNM1 (0.50) DNM1PLA2G1BPLA2G2ATSHRKDM4E
SCHEMBL23988782 0.88 DNM1 (0.38) DNM1LMNATSHRCYP1A2CHRM2
SCHEMBL24562824 0.87 DNM1 (0.48) DNM1PLA2G1BPLA2G2ATSHRKDM4E
SCHEMBL2641854 0.86 ALDH1A1 (0.54) ALDH1A1
SCHEMBL2637468 0.86 ALDH1A1 (0.54) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2022-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377502-B2 Anti-MSR1 antibodies and methods of use thereof CD47, MSR1, LDLR DNM1 1971/4885PLA2G1B 2692/4885PLA2G2A 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.